QT Imaging Holdings (QTI) reported a third-quarter loss of $0.14 per share on revenue of $7.34 million. That loss figure is on the Earnings Whispers normalized basis, and no consensus estimate or Whisper number was available for comparison. The quarter contained one of the most important reimbursement developments in the company's history, and that was undercut by a guidance cut. On November 4, CMS reversed its proposed nonpayment decision and set separate Medicare hospital outpatient payment for diagnostic QTscan exams, effective January 1, 2027. In the same release, QT Imaging lowered its full-year 2026 revenue guidance to roughly $34 million from about $39 million. Management had affirmed the $39 million target on each of the prior three calls. That is the central tension: the long-term commercial pathway improved just as the near-term numbers deteriorated.

The quality of the quarter deserves scrutiny. GAAP net loss narrowed to $0.3 million, or $0.02 per share, from $4.6 million, or $0.47 per share, a year earlier. The improvement is largely accounting. Results included a $2.4 million noncash gain from the change in fair value of the earnout liability, which helps explain the gap between the GAAP figure and the $0.14 normalized loss. Operating performance moved the other way:

• **Operating loss:** widened to $2.4 million from $1.7 million a year ago and $1.9 million in the second quarter.
• **Operating expenses:** climbed to $5.5 million from $4.9 million sequentially.
• **Adjusted EBITDA:** a loss of $1.66 million, slightly worse than the year-ago $1.41 million loss.
• **Gross margin:** held at 41.3%, in line with the 41% of the first two quarters but below last year's 43.0%.

Headline growth remains strong but is clearly decelerating. Revenue rose 75% year over year on 15 scanners versus nine, following growth of 133% in the first quarter and 103% in the second. Sequentially, revenue was essentially flat with the second quarter's $7.4 million. The revised guidance implies roughly $12.7 million in fourth-quarter revenue. Management guided to about 25 scanners for the quarter, 17 of them in the U.S. That is a steep step-up from Q3's 15 units, yet well short of the contracted minimum-order framework, which called for 60 NXC units, 20 for Gulf Medical and seven for Al Naghi in 2026. The company attributed the cut entirely to Saudi and UAE shipments blocked by the Middle East conflict and the effective closure of the Strait of Hormuz. It said U.S. shipments remain on plan but offered no committed date for Gulf deliveries.

The call preserved a credible growth story beyond 2026. Management said the hospital segment opened by the CMS decision was not in its 2027 projections. Several other developments widen the distribution funnel:

• the Premier GPO agreement secured through NXC, which reaches about 4,400 hospitals;
• the first GCC hospital order, from American Hospital Dubai;
• new regulatory approvals in Bahrain, Qatar and Israel;
• a direct sales team now bringing in purchase orders.

The CEO floated roughly 25% U.S.-driven revenue growth for 2027. The Petaluma move doubled manufacturing capacity, the company passed its first FDA inspection with no 483 observations, and women imaged rose to about 13,000. The Medicare pathway does have limits. It covers diagnostic exams, not routine screening, and utilization ramps have historically been slow.

Bears have legitimate ammunition on the balance sheet. Cash fell to $8.4 million from $11.0 million at June 30, and nine-month operating cash burn reached $10.7 million versus $5.9 million a year earlier. Inventory has more than doubled since year-end to $11.5 million, a heavy commitment while Gulf shipments sit in limbo. Long-term debt of $11.4 million now carries a 12% rate, and stockholders' equity has thinned to $2.6 million. There are offsets. Third-quarter operating burn improved to $2.2 million from $4.8 million, and the $7.3 million in receivables was fully collected by the end of October. Still, management did not give a clear answer on runway, which keeps financing risk in view. The NXC/Canon U.S. distribution agreement, which underpins the 60-unit U.S. framework, expires at year-end and has not yet been renewed.

The market had already been pricing much of this caution. Shares closed at $2.29 ahead of the report, down 23.9% from the $3.01 open following the August release. That leaves them 46.7% below the 200-day moving average and 36% below the inter-earnings high of $3.58 set on August 25. The stock touched a 52-week low of $2.01 on November 6 and entered the report only 13.9% above that level. Investor sentiment remained positive but weakened sharply, falling from 0.93 to 0.34. That suggests enthusiasm had cooled considerably before the guidance cut was disclosed. The Earnings Whispers AVWAP reading remains negative, with momentum neutral.

The bottom line is that QT Imaging delivered a genuine strategic win with Medicare payment, but it paired that win with a credibility-denting guidance cut, a still-widening operating loss and a cash position that leaves little margin for further shipment delays. The reimbursement decision and distribution gains strengthen the 2027 setup. Near-term investors will need evidence of three things: Gulf shipments resuming, the NXC agreement being renewed, and funding being secured without heavy dilution.